Epidemiology and Natural History of Psoriatic Arthritis: An Update What Dermatologists Need to Know

Current Dermatology Reports

Volumn 2, Issue 1, 2013, Pages 66-76

  Koolaee, R Michelle ^a   Takeshita, Junko ^b   Ogdie, Alexis ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Epidemiology; Incidence; Prevalence; Psoriasis; Psoriatic arthritis; Risk factors; Screening tools

Indexed keywords

C REACTIVE PROTEIN; RHEUMATOID FACTOR;

ARTHRALGIA; CARDIOVASCULAR DISEASE; DERMATOLOGIST; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; GENDER; HUMAN; INCIDENCE; MASS SCREENING; NAIL DYSTROPHY; OBESITY; PREVALENCE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RISK FACTOR; SMOKING;

EID: 84921496289     PISSN: None     EISSN: 21624933     Source Type: Journal    
DOI: 10.1007/s13671-012-0032-8     Document Type: Review

References (114)

1. Picchianti-Diamanti A, Germano V, Ferlito C, Migliore A, D'Amelio R, Laganà B. Health-related quality of life and disability in patients with rheumatoid, early rheumatoid and early psoriatic arthritis treated with etanercept. Qual Life Res. 2010; 19(6): 821-6.
2. Kavanaugh A, Antoni C, Krueger GG, Yan S, Bala M, Dooley LT. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis. 2006; 65(4): 471-7.
3. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008; 58(6): 1031-42.
4. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009; 68(Suppl 2: ii): 1-44.
5. Sieper J, van der Heijde D, Landewe R, Brandt J, Burgos-Vagas R. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis. 2009; 68: 784-8.
6. Coates LC, Helliwell PS. Disease measurement-enthesitis, skin, nails, spine and dactylitis. Best Pract Res Clin Rheumatol. 2010; 24(5): 659-70.
7. D'Agostino MA, Olivieri I. Enthesitis. Best Pract Res Clin Rheumatol. 2006; 20(3): 473-86.
8. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973; 3(1): 55-78.
9. Alonso JCT, Perez AR, Castrillo JMA, Garcia JB, Noriega JLR, Larrea CL. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol. 1991; 30(4): 245-50.
10. Biondi OC, Scarpa R, Pucino A, Oriente P. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Derm Vene. 1989; 146: 69-71.
11. Helliwell P, Marchesoni A, Peters M, Barker M, Wright V. A re-evaluation of the osteoarticular manifestations of psoriasis. Br J Rheumatol. 1991; 30(5): 339-45.
12. Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994; 33(9): 834-9.
13. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA)-an analysis of 220 patients. Q J Med. 1987; 62(238): 127-41.
14. Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol. 1994; 33(2): 133-8.
15. Yang Q, Qu L, Tian H, Hu Y, Peng J, Yu X. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis. J Eur Acad Dermatol Venereol. 2011; 25(12): 1409-14.
16. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1, 511 patients with plaque-type psoriasis. Br J Dermatol. 2009; 160(5): 1040-7.
17. Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis.
18. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis. 2005; 64(Suppl 2: ii): 3-8.
19. Bennett RM. Psoriatic arthritis. In: McCarty DJ, editor. Arthritis and allied conditions. 9th ed. Philadelphia: Lea & Feb; 1979. p. 645.
20. Fournie B, Crognier L, Arnaud C, Zabraniecki L, Lascaux-Lefebvre V, Marc V. Proposed classification criteria of psoriatic arthritis: a preliminary study in 260 patients. Rev Rhum Engl Ed. 1999; 66(10): 446-56.
21. Dougados M, van der Linden S, Juhlin R, et al. The European spondylarthropathy study group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991; 34(10): 1218-27.
22. McGonagle D, Conaghan PG, Emery P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum. 1999; 42(6): 1080-6.
23. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006; 54(2): 665-73.
24. Vasey F, Espinoza LR. Psoriatic arthropathy. In: Calin A, editor. Spondyloarthropathies. Orlando: Grune & Stratton; 1984. p. 151-85.
25. Johnson SR, Goek ON, Singh-Grewal D, Vlad SC, Feldman BM, Felson DT. Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum. 2007; 57(7): 1119-33.
26. Congi L, Roussou E. Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria. Clin Exp Rheumatol. 2010; 28: 304-10.
27. Chandran V, Schentag CT, Gladman DD. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum. 2007; 57(8): 1560-3.
28. Chandran V, Schentag CT, Gladman DD. Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting. J Rheumatol. 2010; 35(10): 2069-70.
29. D'Angelo S, Mennillo G, Cutro M, Leccese P, Nigro A, Padula A. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. J Rheumatol. 2009; 36(2): 368-70.
30. Gladman DD. Psoriatic arthritis. In: Gordon K, Ruderman E, editors. Psoriasis and psoriatic arthritis. Berlin: Spinger-Verlag; 2005. p. 57-65.
31. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009; 61(2): 233-9. A cohort of 1, 593 patients with psoriasis was assessed over 20, 936 person-years of follow-up to determine predictors of PsA. Psoriasis features associated with a higher risk of PsA were scalp lesions (HR 3. 89, 95 % CI 2. 18-6. 94), nail dystrophy (HR 2. 93, 95 % CI 1. 68-5. 12), and intergluteal/perianal lesions (HR 2. 35, 95 % CI 1. 32-4. 19).
32. Haglund E, Bremander AB, Petersson IF, Strömbeck B, Bergman S, Jacobsson LT. Prevalence of spondyloarthritis and its subtypes in southern Sweden. Ann Rheum Dis. 2011; 70(6): 943-8.
33. Soriano ER, Rosa J, Velozo E, Schpilberg M, Imamura PM, Diaz J. Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based study. Rheumatology (Oxford). 2011; 50(4): 729-34.
34. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol. 2000; 27(5): 1247-50.
35. Andrianakos A, Trontzas P, Christoyannis F, Dantis P, Voudouris C, Georgountzos A. Prevalence of rheumatic diseases in Greece: a cross-sectional population based epidemiological study. The ESORDIG Study J Rheumatol. 2003; 30(7): 1589-601.
36. Saraux A, Guillemin F, Guggenbuhl P, Roux CH, Fardellone P, Le Bihan E. Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis. 2005; 64(10): 1431-5.
37. Boyer GS, Templin DW, Bowler A, Lawrence RC, Heyse SP, Everett DF. Spondyloarthropathy in the community: differences in severity and disease expression in Alaskan Eskimo men and women. J Rheumatol. 2000; 27(1): 170-6.
38. Buschiazzo E, Maldonado-Cocco JA, Arturi P, Citera G, Berman A, Nitsche A. Epidemiology of spondyloarthritis in Argentina. Am J Med Sci. 2011; 341(4): 289-92.
39. Olivieri I, D'Angelo S, Padula A, Palazzi C. The challenge of early diagnosis of psoriatic arthritis. J Rheumatol. 2008; 35(1): 3-5.
40. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of psoriatic arthritis: a systemic review. J Rheumatol. 2008; 35(7): 1354-8.
41. Catanoso M, Pipitone N, Salvarani C. Epidemiology of psoriatic arthritis. Reumatismo. 2012; 64(2): 66-70.
42. Li R, Sun J, Ren LM, Wang HY, Liu WH, Zhang XW. Epidemiology of eight common rheumatic disease in China: a large-scale cross-sectional survey in Beijing. Rheumatology (Oxford). 2012; 51(4): 721-9.
43. Caki{dotless}r N, Pamuk ÖN, Derviş E, Imeryüz N, Uslu H, Benian Ö. The prevalences of some rheumatic diseases in western Turkey: Havsa study. Rheumatol Int. 2012; 32(4): 895-908.
44. Gladman DD. Psoriatic arthritis. Dermatol Ther. 2004; 17(5): 350-63.
45. Leonard DG, O'Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc. 1978; 53(8): 511-8.
46. Carneiro JN, Paula AP, Martins GA. Psoriatic arthritis in patients with psoriasis: evaluation of clinical and epidemiological features in 133 patients followed at the University hospital of Brasília. An Bras Dermatol. 2012; 87(4): 539-44.
47. De Marco G, Cattaneo A, Battafarano N, Lubrano E, Carrera CG, Marchesoni A. Not simply a matter of psoriatic arthritis: epidemiology of rheumatic diseases in psoriatic patients. Arch Dermatol Res. 2012; 304(9): 719-26.
48. Christophers E, Barker JN, Griffiths CE, Daudén E, Milligan G, Molta C. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010; 24(5): 548-54.
49. Li W, Han J, Qureshi AA. Smoking and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012; 71(6): 804-8. A cohort of 94, 874 participants from the Nurses' Health Study II were assessed over 303, 970 person-years of follow-up, with data suggesting that smoking is associated with development of PsA. In this study, 157 incident PsA cases were identified. Compared with never smokers, the relative risk (RR) for developing PsA was 1. 54 for past smokers (95 % CI 1. 06-2. 24) and 3. 13 for current smokers (95 % CI 2. 08-4. 71). With increasing smoking duration or pack-years, the risk of PsA increased monotonically (p for trend < 0. 0001). Of note, this was the largest study to investigate this question.
50. Pattison E, Harrison BJ, Griffiths CE, Silman AJ, Bruce IN. Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann Rheum Dis. 2008; 67(5): 672-6.
51. 2, the RRs for developing PsA were 1. 09 (0. 93-1. 28) for BMIs from 25. 0 to 25. 9, 1. 22 (1. 02-1. 47) for BMIs from 30. 0 to 34. 9 and 1. 48 (1. 20-1. 81) for BMIs ≥35. This raises the question whether weight reduction may be important to prevent PsA among patients with psoriasis.
52. Soltani-Arabshahi R, Wong B, Feng BJ, Goldgar DE, Duffin KC, Krueger GG. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol. 2010; 146(7): 721-6. This study examined the risk factors for developing PsA in a cohort of 943 subjects with dermatologist-diagnosed psoriasis using self-reported questionnaires. They found that BMI at age 18 years was predictive of the development of PsA (odds ratio [OR], 1. 06) (P < 0. 01) over and above control variables.
53. Thumboo J, Uramoto K, Shbeeb MI, O'Fallon WM, Crowson CS, Gibson LE. Risk factors for the development of psoriatic arthritis: a population based nested case control study. J Rheumatol. 2002; 29(4): 757-62.
54. Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses' health study II. Am J Med. 2007; 120(11): 953-9.
55. Eder L, Shanmugarajah S, Thavaneswaran A, Chandran V, Rosen CF, Cook RJ. The association between smoking and the development of psoriatic arthritis among psoriasis patients. Ann Rheum Dis. 2012; 71(2): 219-24. In this case-control study, a multivariate analysis demonstrated that being a current smoker versus a lifetime nonsmoker was inversely associated with PsA (OR 0. 57, p = 0. 002), whereas past smoker versus lifetime nonsmoker status was not significant, similar to the previous study.
56. Eder L, Law T, Chandran V, Shanmugarajah S, Shen H, Rosen CF. Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res (Hoboken). 2011; 63(8): 1091-7. In this case-control study, the cases were patients with recent-onset PsA (n = 159) and controls were psoriasis patients without arthritis (n = 159). Smoking was inversely associated with the development of PsA, with an OR of 0. 6 (95 % CI 0. 36-0. 89). It is important to be aware that the role of smoking as a risk factor for PsA is less clear; data show both direct and inverse correlations.
57. Attwa E, Swelam E. Relationship between smoking-induced oxidative stress and the clinical severity of psoriasis. J Eur Acad Dermatol Venereol. 2011; 25(7): 782-7.
58. Vassalle C, Maffei S, Ndreu R, Mercuri A. Age-related oxidative stress modulation by smoking habit and obesity. Clin Biochem. 2009; 42(7-8): 739-41.
59. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010; 34(3): J258-65.
60. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002; 2(5): 372-7.
61. van Maanen MA, Lebre MC, van der Poll T, LaRosa GJ, Elbaum D, Vervoordeldonk MJ. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum. 2009; 60(1): 114-22.
62. Ogdie A, Langan S, Love T, Haynes K, Shin D, Seminara N, et al. Prevalence and treatment patterns of psoriatic arthritis in the United Kingdom. Rheumatology (Oxford). 2012. doi: 10. 1093/rheumatology/kes324.
63. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005; 53(4): 573.
64. Ash ZR, Tinazzi I, Gallego CC, Kwok C, Wilson C, Goodfield M. Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Ann Rheum Dis. 2012; 71(4): 553-6. Forty-six patients with psoriasis (31 with nail disease) and 21 matched healthy controls (HC) were recruited; 804 entheses of upper and lower limbs were scanned using ultrasonography. Enthesopathy scores were significantly higher in patients with nail disease than in patients without nail disease. Nail psoriasis is likely to be an important risk factor for PsA development.
65. Scarpa R, Soscia E, Peluso R, Atteno M, Manguso F, Del Puente A. Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol. 2006; 33(7): 1315-9.
66. Farber EM, Nall L. Natural history and treatment of scalp psoriasis. Cutis. 1992; 49(6): 396-400.
67. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' health study II. Arch Intern Med. 2007; 167(15): 1670-5.
68. Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation. Rheumatology (Oxford). 2008; 47(5): 718-23.
69. Bhole VM, Choi HK, Burns LC, Vera Kellet C, Lacaille DV, Gladman DD. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford). 2012; 51(3): 552-6.
70. Taylor WJ. Impact of psoriatic arthritis on the patient: through the lens of the WHO international classification of functioning, health, and disability. Curr Rheumatol Rep. 2012; 14(4): 369-74.
71. Leung YY, Ho KW, Zhu TY, Tam LS, Kun EW, Li EK. Testing scaling assumptions, reliability and validity of medical outcomes study short-form 36 health survey in psoriatic arthritis. Rheumatology (Oxford). 2010; 49(8): 1495-501.
72. Lementowski PW, Zelicof SB. Obesity and osteoarthritis. Am J Orthop. 2008; 37: 148-51.
73. Gladman D, Antoni C, Mease P, Clegg D, Nash P. Psoriatic arthritis: epidemiology, clinical features, course and outcome. Ann Rheum Dis. 2005; 64(Suppl II): ii14-7.
74. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology. 2003; 42(12): 1460-8.
75. Bond S, Farewell V, Schentag C, et al. Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis. 2007; 66: 370-6.
76. Simon P, Pfoehler C, Bergner R, Schreiber M, Pfreundschuh M, Assmann G. Swollen joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feet. Clin Exp Rheumatol. 2012; 30(1): 45-50.
77. Cresswell L, Chandran V, Farewell VT, Gladman DD. Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis. Ann Rheum Dis. 2011; 70(2): 305-8.
78. Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perdok RJ, Sasso EH. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther. 2010; 12(3): R113.
79. Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis & Rheumatism. 2009; 61(10): 1373-8.
80. Gladman D, Thavaneswaran A, Chandran V, Cook R. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011; 70: 2152-4.
81. Anderson J, Wells G, Verhoeven A, Felson D. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arth Rheum. 20000; 43(1): 22-9.
82. Lard L, Visser H, Speyer I, Vander Horst-Bruinsma I, Zwinderman A, Breedveld FC, Hazes JM. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001; 111(6): 446-51.
83. Haraoui B, Pope J. Treatment of early rheumatoid arthritis: concepts in management. Semin Arth Rheum. 2011; 40: 371-88.
84. Breedveld F. The value of early intervention in RA-a window of opportunity. Clin Rheumatol. 2011; 30 Suppl 1: S33-9.
85. Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011; 70(12): 2152-4.
86. Khraishi M, Landells I, Heale C, Mugford G, Grouchy B. The Psoriasis and Arthritis Screening Questionnaire (PASQ): a sensitive and specific tool to diagnose psoriatic arthritis patients with high correlation to the CASPAR criteria. Presentation 83rd Annual Conference of the Canadian Dermatology Association 2008.
87. Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007; 57(4): 581-7.
88. Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009; 27(3): 469-74.
89. Dominguez PL, Husni ME, Holt EW, Tyler S, Qureshi AA. Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire. Arch Dermatol Res. 2009; 301(8): 573-9.
90. Gladman DD, Schentag CT, Tom BD, Chandran V, Brockbank J, Rosen C. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis. 2009; 68(4): 497-501.
91. Khraishi M, Mong J, Landelis I. The electronic Psoriasis and Arthritis Screening Questionnaire (ePASQ): a sensitive and specific tool to diagnose psoriatic arthritis patients. J Cutan Med Surg. 2011; 15(3): 143-9.
92. Walsh JA, Callis Duffin K, Krueger GG, Clegg DO. Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. J Rheumatol (in press).
93. Klinkhoff A. Rheumatology: 5. Diagnosis and management of inflammatory polyarthritis. CMAJ. 2000; 162(13): 1833-8.
94. Suresh E. Diagnosis of early rheumatoid arthritis: what the non-specialist needs to know. J R Soc Med. 2004; 97: 421-4.
95. Mease PJ. Inflammatory musculoskeletal disease: identification and assessment. J Rheumatol. 2011; 38: 557-61.
96. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Home Page. 2012(Dec 3). http://www. grappanetwork. org/.
97. Salliot C, Dernis E, Lavie F, et al. Diagnosis of peripheral psoriatic arthritis: recommendations for clinical practice based on data from the literature and experts opinion. Joint Bone Spine. 2009; 76(5): 532-9.
98. Ory P, Gladman D, Mease P. Psoriatic arthritis and imaging. Ann Rheum Dis. 2005; 64(Suppl II): ii55-7.
99. Gutierrez M, Filippucci E, De Angelis R, Filosa G, Kane D, Grassi W. A sonographic spectrum of psoriatic arthritis: "the five targets". Clin Rheumatol. 2010; 29: 133-42.
100. McQueen F, Dalbeth N, Doyle A. MRI in psoriatic arthritis: insights into pathogenesis and treatment response. Curr Rheumatol Rep. 2008; 10: 303-10.
101. Ritchlin C, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009; 68: 1387-94.
102. Tillett W, McHugh N. Treatment algorithms for early psoriatic arthritis: do they depend on disease phenotypes? Curr Rheumatol Rep. 2012; 14(4): 334-42.
103. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012; 71(3): 319-26.
104. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012; 71(1): 4-12.
105. Kingsley GH, Kowalczky A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012; 51(8): 1368-77.
106. Mease PJ. Spondylarthritis: Is methotrexate effective in psoriatic arthritis? Nat Rev Rheumatol. 2012; 8(5): 251-2.
107. Han C, Robinson Jr DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006; 33(11): 2167-72.
108. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum. 2004; 34(3): 585-92.
109. Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum. 2007; 36(4): 203-9.
110. Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum. 2011; 63(5): 1182-9.
111. McHugh NJ, Arumugam R. Mortality and cause of death in psoraitic arthritis. J Rheumatol Suppl. 2012; 89: 32-5.
112. Dubreuli M, Rho YH, Man A, et al. The risk of diabetes in psoriatic arthritis and rheumatoid arthritis. Arthritis Rheum. 2012; 64(S10): S1107.
113. •• Li WQ, Han JL, Manson JE, Rimm EB, Rexrode KM, Curhan GC. Psoriasis and risk of nonfatal cardiovascular disease in U. S. women: a cohort study. Br J Dermatol. 2012; 166(4): 811-8. This study examined the association between PsA and CVD in a large cohort of U. S. women from the Nurses' Health Study II (n = 96, 008). They found a significantly elevated risk of nonfatal CVD, particularly MI, in women with PsA, even after adjusting for traditional cardiovascular risk factors. Adjusted hazard ratios (95 % CI) for nonfatal CVD, nonfatal MI, and nonfatal stroke were 5. 32 (2. 85-9. 94), 7. 4 (3. 5-15. 66), and 3. 18 (1. 02-9. 91) respectively.
114. Khraishi M, MacDonald D, Rampakakis E, Vaillancourt J, Sampalis JS. Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts. Clin Rheumatol. 2011; 30(7): 877-85.